Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol.
The effects of perfusion of an oxygen-carrying perfluorochemical emulsion (Fluosol) in alleviating symptoms of myocardial ischemia during balloon occlusion were examined in a multicenter trial of 245 patients. Severe anginal pain occurred less frequently in patients receiving Fluosol perfusion (21%) than in those receiving routine angioplasty (34%) (p less than 0.05). ST-segment changes at balloon deflation in routine angioplasty patients were significantly greater than in patients who received oxygenated Fluosol perfusion (2.2 +/- 1.2 vs 1.7 +/- 0.9 mm; p less than 0.03). Profound regional wall dysfunction (-561 +/- 224 U) was observed in routine angioplasty patients by 2-dimensional echocardiography. Patients receiving oxygenated Fluosol perfusion, however, maintained near baseline levels of ventricular function (-61 +/- 335 U) during occlusion (p less than 0.0001). Mean global left ventricular ejection fraction was preserved at baseline levels during balloon inflation in patients perfused with oxygenated Fluosol but decreased significantly (p less than 0.001) during occlusion in routine angioplasty patients. A total of 26 complications (19 routine group; 7 perfusion group) was reported. Adverse responses to the perfusate were infrequent, occurring in 1.6 and 2.0% of patients after the test dose and during perfusion, respectively. Thus, transcatheter perfusion with an oxygen-carrying perfluorochemical emulsion is effective in alleviating myocardial ischemia during angioplasty and can be safely administered in this patient population.
Cardiology Division, Georgetown University Medical Center, Washington, DC 20007.
K M
KM
Kent
M W
MW
Cleman
M J
MJ
Cowley
M B
MB
Forman
C C
CC
Jaffe
M
M
Kaplan
S B
SB
King
M W
MW
Krucoff
T
T
Lassar
B
B
McAuley
D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001802:Blood Substitutes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic
D001802:Blood Substitutes; D005466:Fluorocarbons; C050455:fluosol